CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation

PHASE3RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

September 21, 2026

Study Completion Date

October 21, 2026

Conditions
Recurrent Pericarditis
Interventions
DRUG

CardiolRx

The intervention will be administered orally (via syringe) with food twice daily.

Trial Locations (26)

10016

RECRUITING

NYU Langone Health, New York

10032

RECRUITING

Columbia University - New York Presbyterian, New York

RECRUITING

Columbia University - New York Presbyterian, New York

11030

RECRUITING

Lenox Hill Hospital, New York

21044

NOT_YET_RECRUITING

MedStar Health Institute, Columbia

21205

NOT_YET_RECRUITING

Johns Hopkins University, Baltimore

22903

RECRUITING

University of Virginia, Charlottesville

23219

RECRUITING

Virginia Commonwealth University, Richmond

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

RECRUITING

Mayo Clinic, Jacksonville

44195

RECRUITING

Cleveland Clinic, Cleveland

55407

NOT_YET_RECRUITING

Minneapolis Heart Institute, Minneapolis

55905

RECRUITING

Mayo Clinic, Rochester

60208

RECRUITING

Northwestern University, Chicago

77030

RECRUITING

Houston Methodist Hospital, Houston

84112

NOT_YET_RECRUITING

University of Utah Hospital, Salt Lake City

85054

RECRUITING

Mayo Clionic Arizona, Phoenix

92697

NOT_YET_RECRUITING

UCI Health, Irvine

02114

RECRUITING

Massachusetts General Hospital, Boston

05401

RECRUITING

University of Vermont, Burlington

Unknown

RECRUITING

Jewish General Hospital, Montreal

RECRUITING

Hippokration General Hospital, Athens

NOT_YET_RECRUITING

Fatebenefratelli Hospital Milano, Milan

NOT_YET_RECRUITING

University of Padua, Padua

NOT_YET_RECRUITING

University Hospital, Torino

NOT_YET_RECRUITING

University Hospital Udine, Udine

Sponsors
All Listed Sponsors
lead

Cardiol Therapeutics Inc.

INDUSTRY